Ovarian conservation at the time of hysterectomy for benign disease

Obstetrics and Gynecology

Volumn 106, Issue 5, 2005, Pages 1106-

  Dandolu, Vani ^a   Hernandez, Enrique ^a  

^a TEMPLE UNIVERSITY HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BONE DENSITY CONSERVATION AGENT; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR;

CARDIOVASCULAR DISEASE; DECISION SUPPORT SYSTEM; FEMALE; HUMAN; HYSTERECTOMY; NOTE; OSTEOPOROSIS; OVARIECTOMY; OVARY TUMOR; UTERUS DISEASE;

BONE DENSITY CONSERVATION AGENTS; CARDIOVASCULAR DISEASES; DECISION SUPPORT TECHNIQUES; FEMALE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYSTERECTOMY; OSTEOPOROSIS; OVARIAN NEOPLASMS; OVARIECTOMY; UTERINE DISEASES;

EID: 27444441752     PISSN: 00297844     EISSN: 1873233X     Source Type: Journal    
DOI: 10.1097/01.AOG.0000186052.78067.5a     Document Type: Letter

References (5)

1. Parker WH, Broder MS, Liu Z, Shoupe D, Farquhar C, Berek JS. Ovarian conservation at the time of hysterectomy for benign disease. Obstet Gynecol 2005;106:219-26.
2. Armstrong K, Sanford Schwartz, J, Randall T, Rubin SC, Weber B. Hormone replacement therapy and life expectancy after prophylactic oophorectomy in women with BRCA1/2 mutations: a decision analysis. J Clin Oncol 2004;22:1045-54.
3. Colditz GA, Willett WC, Stampfer MJ, Rosner B, Speizer FE, Hennekens CH. Menopause and the risk of coronary heart disease in women. N Engl J Med 1987;316:1105-10.
4. Rossouw JE, Anderson GL, Prentice RL, LaCroix AZ, Kooperberg C, Stefanick ML, et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women’s Health Initiative randomized controlled trial. JAMA 2002;288:321-33.
5. Pell I, Dowie J, Clarke A, Kennedy A, Bhavnani V. Development and preliminary evaluation of a clinical guidance programme for the decision about prophylactic oophorectomy in women undergoing a hysterectomy. Qual Saf Health Care 2002;11:32-9.